Background Malaria remains a major public health problem, due largely to emergence and
widespread P. falciparum drug resistance. WHO recommends artemisinine combination …

Abstract Background In 2006, the Senegalese National Malaria Control Programme
recommended artemisinin-based combination therapy (ACT) as the first-line treatment for …

Background Plasmodium falciparum resistance to chloroquine (CQ) and sulfadoxine-
pyrimethamine (SP) has historically posed a major threat to malaria control throughout the …

Background As a result of the widespread resistance to chloroquine and sulphadoxine-
pyrimethamine, artemisinin-based combination therapy (ACT)(including artemether …

Purpose Artemisin-based combination therapies became the recommended therapy in Côte-
d'Ivoire in 2005, but both chloroquine (CQ) and sulfadoxine/pyrimethamine (SP) have been …

Malaria remains a leading cause of morbidity and mortality in Burkina Faso, which utilizes
artemether–lumefantrine as the principal therapy to treat uncomplicated malaria and …

In Suriname, an artesunate monotherapy therapeutic efficacy trial was recently conducted to
evaluate partial artemisinin resistance emerging in Plasmodium falciparum. We genotyped …

Background Regular monitoring of the levels of anti-malarial resistance of Plasmodium
falciparum is an essential policy to adapt therapy and improve malaria control. This …

Background Due to the threat of emerging anti-malarial resistance, the World Health
Organization recommends incorporating surveillance for molecular markers of anti-malarial …

Antimalarial interventions have yielded a significant decline in malaria prevalence in The
Gambia, where artemether-lumefantrine (AL) has been used as a first-line antimalarial for a …